Thyquidity FDA Approval History
Last updated by Judith Stewart, BPharm on Feb 3, 2022.
FDA Approved: Yes (First approved November 30, 2020)
Brand name: Thyquidity
Generic name: levothyroxine sodium
Dosage form: Oral Solution
Company: Vertice Pharma
Thyquidity (levothyroxine sodium) is a liquid dosage form of levothyroxine for the treatment of hypothyroidism.
- Thyquidity is indicated for:
- Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
- Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
- Thyquidity is administered orally using an oral syringe once daily.
- Adverse reactions include arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash.
Development timeline for Thyquidity
| Date | Article |
|---|---|
| Feb 24, 2021 | Approval Vertice Launches Thyquidity (levothyroxine sodium) Oral Solution |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
